FULGENT GENETICS, INC. Proceeds from Sale of Available-for-sale Securities
FULGENT GENETICS, INC. (FLGT) reported Proceeds from Sale of Available-for-sale Securities of $3.78 million for the 12-month period ending 2017-12-31, per its 10-K filed 2019-03-22.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities · last filed 2019-03-22
- FULGENT GENETICS, INC. proceeds from sale of available-for-sale securities for the quarter ending 2017-12-31 was $0.00.
- FULGENT GENETICS, INC. proceeds from sale of available-for-sale securities for the quarter ending 2017-09-30 was $0.00.
- FULGENT GENETICS, INC. proceeds from sale of available-for-sale securities for the quarter ending 2017-06-30 was $3.78M.
- FULGENT GENETICS, INC. proceeds from sale of available-for-sale securities for the quarter ending 2017-03-31 was $0.00.
- FULGENT GENETICS, INC. proceeds from sale of available-for-sale securities for fiscal 2017 was $3.78M.
- FULGENT GENETICS, INC. proceeds from sale of available-for-sale securities for fiscal 2016 was $0.00.
| Period end | Proceeds from Sale of Available-for-sale Securities 3 month | Proceeds from Sale of Available-for-sale Securities 6 month | Proceeds from Sale of Available-for-sale Securities 9 month | Proceeds from Sale of Available-for-sale Securities 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-22 | $0.00 derived: sum of 2 quarters · filed 2019-03-22 | $3.78M derived: sum of 3 quarters · filed 2019-03-22 | $3.78M 10-K · filed 2019-03-22 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $3.78M derived: sum of 2 quarters · filed 2018-11-09 | $3.78M 10-Q · filed 2018-11-09 | |
| 2017-06-30 | $3.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-13 | $3.78M 10-Q · filed 2018-08-13 | ||
| 2017-03-31 | $0.00 10-Q · filed 2017-05-09 | |||
| 2016-12-31 | $0.00 10-K · filed 2017-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |